JP2016501025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501025A5 JP2016501025A5 JP2015547255A JP2015547255A JP2016501025A5 JP 2016501025 A5 JP2016501025 A5 JP 2016501025A5 JP 2015547255 A JP2015547255 A JP 2015547255A JP 2015547255 A JP2015547255 A JP 2015547255A JP 2016501025 A5 JP2016501025 A5 JP 2016501025A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- polypeptide
- mutated
- protein
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 64
- 229920001184 polypeptide Polymers 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 53
- 235000001014 amino acid Nutrition 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 17
- 102000044162 human IGF1 Human genes 0.000 claims description 17
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 235000018102 proteins Nutrition 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000002243 precursor Substances 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 8
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 6
- 208000021642 Muscular disease Diseases 0.000 claims description 6
- 235000004279 alanine Nutrition 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 4
- 230000020763 muscle atrophy Effects 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 6
- 208000027747 Kennedy disease Diseases 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 208000001076 sarcopenia Diseases 0.000 description 4
- 230000012010 growth Effects 0.000 description 3
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010049565 Muscle fatigue Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261738475P | 2012-12-18 | 2012-12-18 | |
| US61/738,475 | 2012-12-18 | ||
| PCT/IB2013/060985 WO2014097116A1 (en) | 2012-12-18 | 2013-12-16 | Stabilized insulin-like growth factor polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501025A JP2016501025A (ja) | 2016-01-18 |
| JP2016501025A5 true JP2016501025A5 (cg-RX-API-DMAC7.html) | 2017-01-26 |
| JP6499080B2 JP6499080B2 (ja) | 2019-04-10 |
Family
ID=50073229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015547255A Active JP6499080B2 (ja) | 2012-12-18 | 2013-12-16 | 安定化されたインスリン様成長因子ポリペプチド |
Country Status (36)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3052123A1 (en) * | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| KR20180137487A (ko) * | 2016-03-04 | 2018-12-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도 |
| US10953074B2 (en) * | 2017-01-08 | 2021-03-23 | Richard D. Lippman | Composition and method for improving sensorineural hearing |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| EP3813861A4 (en) * | 2018-06-27 | 2022-08-10 | Juvena Therapeutics, Inc. | HEPARIN-ASSOCIATED POLYPEPTIDES AND THEIR USES |
| CN109053875B (zh) * | 2018-08-31 | 2021-06-29 | 重庆大学 | 突变型igf-1、重组质粒、重组蛋白及应用 |
| RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
| CN110642937B (zh) * | 2019-10-11 | 2021-04-06 | 南开大学 | 多肽衍生物、纳米纤维及其应用 |
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| CN117999278A (zh) | 2021-06-21 | 2024-05-07 | 裘美娜治疗公司 | 再生性多肽及其用途 |
| EP4652282A2 (en) * | 2023-11-14 | 2025-11-26 | Cavalry Biosciences, Inc. | Compositions for targeting muscle cells and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| WO2000040612A1 (en) * | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| WO2000040613A1 (en) | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| US7083970B2 (en) | 2001-04-19 | 2006-08-01 | The Scripps Research Institute | Methods and compositions for the production of orthogonal tRNA-aminoacyl tRNA synthetase pairs |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| CA2594023C (en) * | 2005-01-07 | 2015-07-14 | Regeneron Pharmaceuticals, Inc. | Igf-i fusion polypeptides and therapeutic uses thereof |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| CN101466398A (zh) * | 2006-06-09 | 2009-06-24 | 诺瓦提斯公司 | 稳定的胰岛素样生长因子多肽 |
| MX2008015726A (es) | 2006-06-09 | 2008-12-19 | Novartis Ag | Polipeptidos de factor de crecimiento de tipo insulina estabilizada. |
| ES2784926T3 (es) | 2007-12-21 | 2020-10-02 | Novartis Ag | Vector de expresión de mamífero |
| HUE035240T2 (hu) | 2009-04-27 | 2018-05-02 | Novartis Ag | Készítmények és eljárások az izomerõ növelésére |
| WO2011011073A1 (en) * | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| US10030063B2 (en) | 2012-12-18 | 2018-07-24 | Novartis Ag | Production of therapeutic proteins in genetically modified mammalian cells |
| EP3052123A1 (en) | 2013-10-02 | 2016-08-10 | Novartis Ag | Insulin-like growth factor mimetics for use in therapy |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
-
2013
- 2013-12-16 MA MA38153A patent/MA38153B1/fr unknown
- 2013-12-16 BR BR112015013708-3A patent/BR112015013708B1/pt not_active IP Right Cessation
- 2013-12-16 CN CN201380066090.8A patent/CN105121462B/zh active Active
- 2013-12-16 NZ NZ708091A patent/NZ708091A/en not_active IP Right Cessation
- 2013-12-16 CA CA2894976A patent/CA2894976C/en active Active
- 2013-12-16 WO PCT/IB2013/060985 patent/WO2014097116A1/en not_active Ceased
- 2013-12-16 HR HRP20191965TT patent/HRP20191965T1/hr unknown
- 2013-12-16 MX MX2015007932A patent/MX363021B/es unknown
- 2013-12-16 CU CUP2015000064A patent/CU24308B1/xx unknown
- 2013-12-16 SI SI201331611T patent/SI2935320T1/sl unknown
- 2013-12-16 PL PL13828987T patent/PL2935320T3/pl unknown
- 2013-12-16 EA EA201591165A patent/EA034356B1/ru not_active IP Right Cessation
- 2013-12-16 MY MYPI2015001207A patent/MY174820A/en unknown
- 2013-12-16 JP JP2015547255A patent/JP6499080B2/ja active Active
- 2013-12-16 AP AP2015008440A patent/AP2015008440A0/xx unknown
- 2013-12-16 HU HUE13828987A patent/HUE047386T2/hu unknown
- 2013-12-16 KR KR1020157018991A patent/KR102182523B1/ko active Active
- 2013-12-16 US US14/651,686 patent/US10167329B2/en active Active
- 2013-12-16 PE PE2019002049A patent/PE20200894A1/es unknown
- 2013-12-16 PE PE2015001039A patent/PE20151612A1/es not_active Application Discontinuation
- 2013-12-16 EP EP19191570.1A patent/EP3626735A1/en not_active Withdrawn
- 2013-12-16 CR CR20200079A patent/CR20200079A/es unknown
- 2013-12-16 SG SG11201503782PA patent/SG11201503782PA/en unknown
- 2013-12-16 ES ES13828987T patent/ES2756330T3/es active Active
- 2013-12-16 DK DK13828987T patent/DK2935320T3/da active
- 2013-12-16 AU AU2013365796A patent/AU2013365796B2/en not_active Ceased
- 2013-12-16 EP EP13828987.1A patent/EP2935320B1/en active Active
- 2013-12-16 RS RS20191416A patent/RS59545B1/sr unknown
- 2013-12-16 LT LT13828987T patent/LT2935320T/lt unknown
- 2013-12-16 PT PT138289871T patent/PT2935320T/pt unknown
-
2015
- 2015-05-08 TN TNP2015000182A patent/TN2015000182A1/fr unknown
- 2015-06-04 PH PH12015501271A patent/PH12015501271A1/en unknown
- 2015-06-11 IL IL239387A patent/IL239387A0/en active IP Right Grant
- 2015-06-17 CL CL2015001708A patent/CL2015001708A1/es unknown
- 2015-06-17 SA SA515360603A patent/SA515360603B1/ar unknown
- 2015-06-18 CR CR20150324A patent/CR20150324A/es unknown
- 2015-06-18 GT GT201500168A patent/GT201500168A/es unknown
- 2015-07-17 EC ECIEPI201531046A patent/ECSP15031046A/es unknown
-
2019
- 2019-11-19 CY CY20191101212T patent/CY1122309T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501025A5 (cg-RX-API-DMAC7.html) | ||
| US11365232B2 (en) | Interleukin-2 fusion proteins and uses thereof | |
| US11098099B2 (en) | Interleukin-2 fusion proteins and uses thereof | |
| ES2808853T3 (es) | Cadenas ligeras comunes y procedimientos de uso | |
| TWI830974B (zh) | 與 hla-a2/mage-a4 結合之抗體 | |
| ES2775207T3 (es) | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA | |
| KR20230141929A (ko) | Ｆc-함유 폴리펩타이드의 안정화 | |
| BR112021011939A2 (pt) | Anticorpo que se liga a cd3, anticorpos que se ligam a cd3 e tyrp-1, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3, composição farmacêutica e usos do anticorpo | |
| JP2021533779A (ja) | 操作された二重特異性タンパク質 | |
| WO2007114319A1 (ja) | 抗体の血中動態を制御する方法 | |
| JP2024153847A (ja) | 抗体のＦｃ領域改変体 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| EP3227328A1 (en) | Domain-exchanged antibody | |
| KR20160021196A (ko) | 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드 | |
| KR20180043841A (ko) | 키메라 항원 수용체 및 이의 용도 | |
| US20210041163A1 (en) | Method for selecting antibodies with modified fcrn interaction | |
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| CN104098698A (zh) | 一种抗cd3抗体及其制法和应用 | |
| AU2018302343B2 (en) | Single chain vh and heavy chain antibodies | |
| JP2024500354A (ja) | ヘテロ二量体化のための直交変異 | |
| WO2017055395A1 (en) | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules | |
| WO2024183527A1 (en) | Il-2 variants and uses thereof | |
| RU2797464C2 (ru) | Слитые молекулы эктодомена рецептора tgf-бета и их применения | |
| CN110655577A (zh) | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 | |
| WO2025002113A1 (zh) | 一种人血小板生成素受体激动剂的融合蛋白 |